Eugene

[email protected]

LATEST

AbbVie, Google-Funded Calico Invest Additional $1 Billion in Age-Related R&D Pact
By

By
AbbVie and Calico, a research and development (R&D) company focused on aging research and therapeutics, and funded by Alphabet, the parent company of Google, have invested an additional $1 billion…

FDA Approves First Drug with API Derived from Marijuana
By

By
The US Food and Drug Administration (FDA) has approved Epidiolex (cannabidiol [CBD]) oral solution from GW Pharmaceuticals, a London-based biopharmaceutical company, for treating seizures associated with two rare forms of…

Mustang Bio Opens CAR-T Cell-Therapy Manufacturing Facility
By

By
Mustang Bio, a New York-headquartered clinical-stage biopharmaceutical company and a subsidiary of the biopharmaceutical company, Fortress Biotech, has opened a chimeric antigen receptor (CAR) T-cell cell-therapy manufacturing facility at the…

BI To Invest $267 Million in New Biologics Development Center
By

By
Boehringer Ingelheim (BI) plans to invest EUR 230 million ($267 million) in a new biologicals development center (BDC) at the company’s research and development (R&D) site in Biberach, Germany. “The…

FDA Closes Inspection on Biocon’s Sterile Drug-Product Manufacturing Facility
By

By
The US Food and Drug Administration (FDA) has issued an Establishment Inspection Report (EIR) to Biocon, a Bangalore, India-based pharmaceutical company, for its sterile drug-product manufacturing facility in Bangalore. The…

GE Healthcare To Spin Off As Stand-Alone Company
By

By
General Electric (GE) has announced plans to spin off GE Healthcare, its healthcare business, as a stand-alone company, following results from a strategic review. The plan is part of a…

Novacap To Acquire CDMO PCI Synthesis
By

By
Novacap, a Lyon, France-headquartered company providing custom manufacturing services for pharmaceuticals, advanced specialties and cosmetics, has agreed to acquire PCI Synthesis, a Newburyport, Massachusetts-based contract development and manufacturing organization (CDMO)…

WuXi Biologics Begins Construction of ADC Service Center in China
By

By
WuXi Biologics, part of WuXi AppTec, a Shanghai, China-headquartered contract service provider, has begun construction of an antibody-drug conjugate (ADC) service center in Wuxi, China. The $20-million 6,000-square-meter facility will…

Bipartisan Group of Senators Ask FDA to Report Drug-Shortage Solutions to Congress
By

By
A bipartisan group of 31 US senators has asked US Food and Drug Administrator (FDA) Commissioner Scott Gottlieb to have the agency provide recommendations to Congress on how to address…

FDA Provides Updates on Certain Drug Shortages
By

By
Douglas Throckmorton, the Deputy Director for Regulatory Programs for the Center for Drug Evaluation and Research at the US Food and Drug Administration (FDA), provided an update on how the…